# Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy

> **NCT06976021** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Maria Sklodowska-Curie National Research Institute of Oncology** · enrollment: 60 (estimated)

## Conditions studied

- Triple Negative Breast Cancer
- Uterine Cervical Cancer
- Uterine Corpus Cancer
- Malignant Melanoma
- Clear Cell Renal Cell Carcinoma

## Interventions

- **DIAGNOSTIC_TEST:** Baseline 89-Zr Pembrolizumab Immuno PET-CT
- **DIAGNOSTIC_TEST:** Proteomic assay
- **DIAGNOSTIC_TEST:** Follow-up 89-Zr Pembrolizumab Immuno PET-CT

## Key facts

- **NCT ID:** NCT06976021
- **Lead sponsor:** Maria Sklodowska-Curie National Research Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06
- **Primary completion:** 2029-12
- **Final completion:** 2029-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06976021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06976021, "Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06976021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*